Ovarian Cancer Treatment Named Breakthrough Therapy with Potential in Advanced Prostate Cancers

Ovarian Cancer Treatment Named Breakthrough Therapy with Potential in Advanced Prostate Cancers
An approved therapy for advanced ovarian cancer — Rubraca (rucaparib) by Clovis Oncology — has been designated a  breakthrough therapy  by the U.S. Food and Drug Administration as a potential treatment for metastatic castration-resistant prostate cancer (mCRPC) patients with BRCA mutations. This FDA designation is given to speed the development of medications that might treat serious conditions and potentially provide an improvement on available therapies. “We hope the decision by the FDA to grant this Breakthrough Therapy designation for Rubraca offers encouragement to the prostate cancer community, and we will do our best to make Rubraca available to eligible prostate cancer patients as quickly as possible,” Patrick J. Mahaffy, president and CEO of Clovis Oncology, said in a press release. About a quarter of advanced prostate cancers show mutations in BRCA1, BRCA2 or other genes encoding proteins that repair damaged DNA. These tumors are more sensitive to further DNA damage, and often respond well to treatments that block other proteins involved in DNA repair. Rubraca is an oral medicine that inhibits PARP1, PARP2, and PARP3 enzymes, which play a key role in DNA repair when the BRCA proteins are not functioning properly. The FDA based its decision on preliminary results from 
Subscribe or to access all post and page content.